van der Heijde D, et al. - The long-term effectiveness and safety results of adalimumab in patients with nonradiographic axial spondyloarthritis (nr-axSpA) from the open-label ABILITY-1 extension was presented by the experts. They also assessed the relationship between clinical and magnetic resonance imaging (MRI) remission and impact of sustained clinical remission on physical function. Results suggested that through 3 years, sustained clinical and functional improvements were seen with adalimumab therapy. This therapy also suppressed the MRI axial inflammation, which was more in patients who achieved clinical remission. An association of sustained clinical remission and increased attainment of normal physical function was seen. Findings demonstrated safety profile of adalimumab was consistent with prior studies.